<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02130167</url>
  </required_header>
  <id_info>
    <org_study_id>CMRPG8C0601</org_study_id>
    <nct_id>NCT02130167</nct_id>
  </id_info>
  <brief_title>Low Concentration Atropine for Myopia Progression in School Children</brief_title>
  <official_title>Low Concentrations of Atropine for Controlling Myopia Progression in School Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myopia is the leading cause of blindness in Taiwan. The younger children with myopia, the
      higher risk of high myopia in later life and complications such as retinal detachment and
      maculopathy will occur. We have reported the low concentration of atropine (0.05%) with the
      effect on retarding the myopia progression. Recently the 0.01% atropine was also reported
      effective and with less visual side effects such as mydriasis. The aim of this study is to
      compare the efficacy in controlling myopia progression and visual side effects of 2 low
      concentration of atropine(0.05% vs 0.01%) in children aged 6-12 years with myopia of at least
      -0.5 diopters (D) and astigmatism of -1.50 D or less.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cycloplegic spherical refraction change</measure>
    <time_frame>1 year</time_frame>
    <description>Cycloplegic spherical refraction change is the main indicator of the myopia progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Axial length change</measure>
    <time_frame>1 year</time_frame>
    <description>Axial length change is another indicator of the myopia progression.Using non-contact biometry. unit: millimeter(mm)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>pupil size</measure>
    <time_frame>6 months</time_frame>
    <description>Using computer scaling software. unit: millimeter(mm)</description>
  </other_outcome>
  <other_outcome>
    <measure>accommodation</measure>
    <time_frame>6 months</time_frame>
    <description>Using accommodometer to measuer accommodation. Unit: diopeter</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Questionnaire written by patients and their parents about how many hours per week of near work (ex. computer/video game, reading, piano playing...) and outdoor activities, the compliance of atropine use, discomfort after atropine use (ex. photophobia or blurred vision when near work)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Myopia Progression</condition>
  <arm_group>
    <arm_group_label>0.01% Atropine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.05% Atropine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atropine</intervention_name>
    <description>Compare different concentrations of atropine eye drops (0.01% vs 0.05%) in the efficacy of controlling myopia progression and side effects of atropine</description>
    <arm_group_label>0.01% Atropine</arm_group_label>
    <arm_group_label>0.05% Atropine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Myopia of at least -0.5 diopters (D) and astigmatism of -1.50 D or less.

        Exclusion Criteria:

        strabismus, amblyopia. cataract, glaucoma or any ocular diseases ocular surgery history
        systemic diseases (ex. asthma, heart disease...)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pei-Chang Wu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Ophthalmology, Kaohsiung Chang Gung Memorial Hospital, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2014</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myopia progression</keyword>
  <keyword>Low concentration atropine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

